COMMUNIQUÉS West-GlobeNewswire

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
14/05/2026
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support [...]
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
14/05/2026
Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026 Presented new [...]
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
14/05/2026
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million Q1 2026 fully [...]
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
14/05/2026
Includes Full Exercise of $15.0 million Over-Allotment Option MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for [...]
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center [...]
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
14/05/2026
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Enhanced the company’s portfolio with an exclusive license for, CUE-221, a Phase 2 [...]
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
14/05/2026
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled [...]
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
First Tracks launched April 20 th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, [...]
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
14/05/2026
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen [...]
BioStem Technologies Reports First Quarter 2026 Financial Results
14/05/2026
POMPANO BEACH, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
CapsoVision Reports First Quarter 2026 Financial Results
14/05/2026
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
14/05/2026
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
14/05/2026
Strengthened balance sheet and advancing clinical pipeline with multiple catalysts expected through 2027 SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “ [...]
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
14/05/2026
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and [...]
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
14/05/2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Precipio Announces Q1 2026 Financial Results
14/05/2026
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc [...]
HEALIOS K.K. to Present at Jefferies Global Healthcare Conference
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference in New York City as [...]
SRx Health Solutions Announces Fiscal Second Quarter 2026 Results for Quarter Ended March 31, 2026
14/05/2026
Q2 FY26 Marks Operational Inflection Point with Sequential 23% Revenue Growth and 44% Adjusted EBITDA Loss 1 Improvement Strengthened Liquidity and Working Capital Position with Cash of $20.5 million as of Quarter End [...]

Pages